| ORIGINAL ARTICLE |
|
| Year : 2009 | Volume
: 12
| Issue : 2 | Page : 42-45 |
|
|
Antiphospholipids antibodies and migraine
YW Nyandaiti1, SA Bwala1, AA Gadzama2, W Gashua1, D Bubokk3
1 Department of Medicine, University of Maiduguri, Nigeria
2 Department of Chemical Pathology, University of Maiduguri, Nigeria
3 Department of Immunology, University of Maiduguri, Nigeria
Correspondence Address:
Y W Nyandaiti
Department of Medicine, University of Maiduguri
Nigeria
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
Background: Antiphospholipids antibodies has been associated with non-thrombotic neurological conditions such as migraine. We set out to estimate the concentration of antiphospholipids antibody among patients with migraine and normal population.
Methods: This is prospective case-control study of 158 subjects including 82 migraine patients who fulfilled the International Headache Society criteria for the diagnosis of migraine headache and 76 age and sex-matched controls who were mostly hospital staff and medical students. Blood samples were taken for quantification of antiphospholipids antibodies.
Results: There were 28 males and 54 females among the migraine patients and 30 males and 46 females among the controls. Their mean ages were 28.8 ± 8.4 years and 26.4 ± 3.9 years, respectively. Migraine patients had increased level of aPL (IgG anti β2 GP1) 27.76 ± 14.47IU/ml compared to the normal healthy adults (21.43 ± 9.4IU/ml) (p<0.05). Similarly, antiphospholipid antibodies was significantly elevated in migraine patients with aura compared to those without aura, (χ =0.037; p<0.05). The frequency of migraine attacks correlated positively with the concentration of IgG anti β2 GP1; ( p<0.05).
Conclusion: We demonstrated increased serum level of IgG anti β2 GP1 among migraine patients. The frequency of migraine attacks correlated positively with the concentration of IgG anti β2 GP1. |
|
|
|
| [PDF]* |
|
 |
|
